Arch Biopartners Inc V.ARCH

$3.35- Extremely Undervalued in Comparison to Phase II peers

[Riverfolk]

lets not forget that we are extremely undervalued compared to our Phase II peer group .

REMEMBER THAT WE ARE NOW A PHASE III COMPANY

Current market cap 162 mil US,

• we are 1.38 from NYSE uplisting requirements
• we are 2.38 from Nasdaq uplisting requirements 

We are waiting on Phase III Human Clinical Trial Health Canada Approval  a 20 billion a year unmet market.

• BLU is currently 795 mil market cap for Chronic Cough (Phase 2)
• VXRT is currently 888 mil market cap  US Oral Vaccines
• SAVA is 2 billion US market cap for Blood Cancer (Phase 2)
• CYDY is 1.1  billion US market cap for Antibodies
• TRIL was 2.2 billion buyout (Phase 2)
•  

We recieved positive Phase II data, enough for the governement to fully fund Phase III/ there is no reason why we are not at a 695 million market cap of $11.20 on the low side and $35 on the high end. We have fully patented new mechanism of action with a drug library. IMHO we will be 10x this current price if data deems it worthy.

[C10H12N2]

I find it hilariously hypocritical that you would place Bellus Health in comparison to Arch and Arch is not chasing Chronic Cough. Yet an actual company with Chronic Cough in it's portfolio at Phase II and proven to be 110% better than the current leading Chronic Cough drug by Merck. That company is valued at U$S5M which is 790M $ less than your example. Yet, you ranted about Algernon

[Riverfolk]

This post has been removed in accordance with Community Policy